ArticleOPEN ACCESS

Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis, (Front.Immunol, (2024), 15, (1480676), 10.3389/fimmu.2024.1480676)

Frontiers in Immunology
DOI: 10.3389/fimmu.2024.1535051
1Citations
Citations of this article
3Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In the published article, an author name was incorrectly written as “Fernando Castellanos”. The correct spelling is “Fernando Castellanos-Pinedo”. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Author supplied keywords

Cite

CITATION STYLE

APA

Rodríguez-Jorge, F., Fernández-Velasco, J. I., Villarrubia, N., Gracia-Gil, J., Fernández, E., Meca-Lallana, V., … Villar, L. M. (2024). Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis, (Front.Immunol, (2024), 15, (1480676), 10.3389/fimmu.2024.1480676). Frontiers in Immunology. Frontiers Media SA. https://doi.org/10.3389/fimmu.2024.1535051

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free